Maurie Markman, MD: How do PARP inhibitors impact the landscape of ovarian cancer treatment, from your perspective, as of today? Justin Chura, MD: When we’re talking about the recurrent setting and we ...
Studies by a Dana-Farber Cancer Institute (DFCI)-led research team suggest that disabling immune suppression mediated by a specific type of macrophage may boost the effectiveness of poly ADP ribose ...
Results of a phase II trial of the PARP inhibitor olaparib, presented at the meeting of the Society of Gynecologic Oncology, showed that maintenance therapy with olaparib significantly improved PFS in ...
The use of PARP inhibitors and I/O therapy is examined for the treatment of triple-negative breast cancer, and the MEDIOLA and SWOG S1416 trials are reviewed. The first cohort of the MEDIOLA trial ...
PARP inhibitors, used to treat patients with cancer of the breast, ovaries, prostate and pancreas, work by inducing persistent DNA gaps in tumor cells with BRCA1 and BRCA2 mutations. The discovery ...
Findings from a new study reveal that PARP inhibitors, an emerging class of drugs being studied in cancer clinical trials, may be enhanced by combining them with inhibitors targeting an oncogene known ...
"The use of PARP inhibitors is a promising approach to enhance targeted radionuclide therapy for neuroendocrine cancer," said Samuel Adant, a member of the research team from the CHU de Québec -- ...
Forbes contributors publish independent expert analyses and insights. I cover cancer science, treatments and attitudes. Zejula would be given as maintenance therapy―indefinitely, until the cancer ...
Platinum-resistant recurrent epithelial ovarian cancer carries a bleak prognosis, with single-agent chemotherapy yielding ...
A new study confirmed an elevated risk for myelodysplastic syndrome or acute myeloid leukemia (MDS/AML) after poly(ADP-ribose) polymerase (PARP) inhibitor therapy in women with ovarian cancer and ...
The addition of Lynparza to maintenance therapy with Avastin improved time to disease progression in women with advanced ovarian cancer, according results of the PAOLA-1/ENGOT-ov25 trial. The addition ...
DENVER, Colo. - Cancer of the neuroendocrine system is a moving target with managed treatment aimed at palliative care rather than a cure. Patients with neuroendocrine tumors (NETs) may experience ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback